CLINICAL EFFECTIVENESS AND INFLUENCE OF OLMESARTAN ON VASCULAR STIFFNESS IN PATIENTS
WITH CHD IN COMBINATION WITH ARTERIAL HYPERTENSION OF 1–2 DEGREE 

Tomashevskaya Yuliya Anatol'evna, Candidate of medical sciences, associate professor, sub-department of therapy, Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia), T.julia74@mail.ru
Matrosova Irina Borisovna, Candidate of medical sciences, associate professor, sub-department of therapy,
Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia), matrosovaib@mail.ru
Mel'nikova Evgeniya Aleksandrovna, Postgraduate student, Medical Institute, Penza State University
(40 Krasnaya street, Penza, Russia), melnikova1910@gmail.com

616.12-008.331.1

Background. The purpose of the present study is to evaluate the clinical effect of olmesartan treatment on the arterial stiffness in patients with proven coronary heart disease (CHD) and arterial hypertension of 1–2 degrees.
Materials and methods. 20 patients with CHD and hypertension were examined: 10 men and 10 women, mean age – 59,3 ± 7,5 years. Arterial stiffness was assessed by using the volume sphygmography device VaSera-1000 («Fukuda Denshi», Japan). Daily indicators of arterial stiffness were analyzed by the ambulatory blood pressure monitor BPLab («Peter Telegin», Russia), with estimation of regional stiffness by the Vasotens program. All patients were treated Kardosal ® (olmesartan medoxomil) for 24 weeks.
Results. After 24 weeks of treatment the authors revealed reduction of office systolic and diastolic blood pressure, as well as regression of central aortic pressure. There was a significant decrease in the dynamics of the aortic augmentation index by 35 %, the index of arterial stiffness by 17,4 % (p < 0,05). According to volume sphygmography a significant decrease was registered in all characteristics: PWV – up to 7,5 ± 2,7 m/s (19 %, p < 0,05), R-PWV – up to 14,04 ± 2,6 (11,6 %), L-PWV – up to 13,7 ± 2,3 (11,7 %, p < 0,05). CAVI1 and L-CAVI1 levels totaled 8,7 ± 1,9 8,2 ± 2,5 (p < 0,05).
Conclusions. The olmesartan therapy for 24 weeks, besides normalization of peripheral arterial pressure, authentically improves characteristics of daily central aortal pressure and also indicators of regional arterial rigidity.

arterial stiffness, olmesartan, arterial hypertension, coronary heart disease.

1. Malacco E., Omboni S. J. Hypertens. 2010, vol. 11, pp. 2342–2350.
2. Palatini P., Casiglia E., Julius S., Pessina A. C. Arch. Intern. Med. 1999, vol. 159, pp. 585–592.
3. Laurent S., Cockcroft J., L. van Bortel et al. Eur. Heart. J. 2006, vol. 27, pp. 2588–2605.
4. Milyagin V. A., Komissarov V. B. Arterial'naya gipertenziya [Arterial hypertension]. 2010, vol. 16, no. 2, pp. 134–143.
5. Williams B. Circulation. 2006, vol. 113, pp. 1213–1225.
6. Moiseeva N. M., Ponomarev Yu. A., Sergeeva M. V., Rogoza A. N. Arterial'naya gipertenziya [Arterial hypertension]. 2007, vol. 13, no. 1, pp. 34–38.
7. Smith R. D., Yokoyama H., Averill D. B. et al. Am. J. Cardiovasc. Drugs. 2006, no. 6, pp. 335–342.
8. Flizer D. et al. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular therapy and preventive measures]. 2010, no. 9 (7), pp. 1–21.
9. Liu H., Yambe T., Zhang X. et al. Tohoko J. Exp. Med. 2005, vol. 207, no. 4, pp. 263–270.
10. Filipovsky J., Ticha M., Cufkova R. Blood press. 2005, vol. 14, no. 1, pp. 45–52.
11. Makolkin V. I. Kardiologiya [Cardiology]. 2006, no. 2, pp. 83–85.